欧盟药敏试验委员会结核分枝杆菌MIC测定参考肉汤微量稀释法的多中心验证
EUCAST抗分枝杆菌药敏试验分委会于2017至2018年在四个实验室前瞻性评估结核分枝杆菌MIC测定方案,对参考株H37Rv测定异烟肼、左氧氟沙星和阿米卡星的MIC。肉汤微量稀释法(BMD)和固体培养基稀释法(SMD)在两种接种浓度下进行,结果显示两种方法重复性良好,最终选择BMD作为EUCAST参考方法。
要点
- BMD和SMD对三种药物的批内和批间一致率均>95%在±1个稀释度内。
- BMD的MIC众数(范围):异烟肼0.03(0.015-0.06)mg/L,左氧氟沙星0.25(0.25-0.5)mg/L,阿米卡星0.5(0.5-1.0)mg/L。
- EUCAST最终选择BMD作为结核分枝杆菌复合群MIC测定的参考方法。
核心结论
- BMD和SMD均具有可重复性,可作为结核分枝杆菌复合群MIC测定的参考方法,最终BMD被选为EUCAST参考方法。
研究设计与样本
- 2017至2018年在四个AMST实验室开展前瞻性多中心研究,评估MIC测定方案。
- 对参考株结核分枝杆菌H37Rv ATCC 27294测定异烟肼、左氧氟沙星和阿米卡星的MIC。
- 采用Middlebrook 7H9肉汤微量稀释法(BMD)和Middlebrook 7H10固体培养基稀释法(SMD),各使用两种接种浓度。
主要发现
- 按照EUCAST参考方案,三种药物在两种方法中批内和批间一致率均>95%在±1个MIC稀释度内。
- BMD的MIC众数(范围):异烟肼0.03(0.015-0.06)mg/L,左氧氟沙星0.25(0.25-0.5)mg/L,阿米卡星0.5(0.5-1.0)mg/L。
- SMD的MIC众数(范围):异烟肼0.12(0.06-0.25)mg/L,左氧氟沙星0.5(0.12-0.5)mg/L,阿米卡星0.5(0.5-1.0)mg/L。
临床怎么用
- EUCAST参考BMD法可用于设定新旧抗结核药物的流行病学折点值和临床折点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The first objective of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) subcommittee for antimycobacterial susceptibility testing (AMST), launched in 2016, was to set a reference method for determining the MICs of antituberculous agents, since many protocols are used worldwide and a consensus one is needed for the determination of microbiological breakpoints. METHODS: During 2017 and 2018, MIC determination protocols were evaluated prospectively in a multicentre study within the four AMST laboratories. MIC results were obtained for isoniazid, levofloxacin and amikacin on the reference strain Mycobacterium tuberculosis H37Rv ATCC 27294. Broth microdilution (BMD) in Middlebrook 7H9 and solid medium dilution (SMD) in Middlebrook 7H10 were performed using two inoculum concentrations. MICs were interpreted with regard to visual and 99% inhibition after 7, 14 or 21 days of incubation for BMD and 21 days for SMD. RESULTS: Following the EUCAST reference protocol, intra- and inter-assay agreements were within ±1 MIC dilution for >95% of the observations for the three drugs in both methods. MIC values, presented as MIC mode (range) for BMD and SMD respectively, were: 0.03 (0.015-0.06) mg/L and 0.12 (0.06-0.25) mg/L for isoniazid, 0.25 mg/L (0.25-0.5) and 0.5 mg/L (0.12-0.5) for levofloxacin, and 0.5 mg/L (0.5-1.0) and 0.5 mg/L (0.5-1.0) for amikacin. CONCLUSIONS: Both SMD and BMD were reproducible and eligible as a reference method for MIC determination of the Mycobacterium tuberculosis complex (MTBC). BMD was finally selected as the EUCAST reference method. From now on it will be used to set epidemiological cut-off values and clinical breakpoints of new and old antituberculous agents.
引用
- Schön T, Werngren J, Machado D, et al. Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on Mycobacterium tuberculosis. Clin Microbiol Infect. 2020. PMID: 33198949. doi:10.1016/j.cmi.2020.10.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。